Literature DB >> 18780145

Role of protein flexibility in the design of Bcl-X(L) targeting agents: insight from molecular dynamics.

William Novak1, Hongming Wang, Goran Krilov.   

Abstract

Detailed understanding of protein-ligand interactions is crucial to the design of more effective drugs. This is particularly true when targets are protein interfaces which have flexible, shallow binding sites that exhibit substantial structural rearrangement upon ligand binding. In this study, we use molecular dynamics simulations and free energy calculations to explore the role of ligand-induced conformational changes in modulating the activity of three generations of Bcl-X(L) inhibitors. We show that the improvement in the binding affinity of each successive ligand design is directly related to a unique and measurable reduction in local flexibility of specific regions of the binding groove, accompanied by the corresponding changes in the secondary structure of the protein. Dynamic analysis of ligand-protein interactions reveals that the latter evolve with each new design consistent with the observed increase in protein stability, and correlate well with the measured binding affinities. Moreover, our free energy calculations predict binding affinities which are in qualitative agreement with experiment, and indicate that hydrogen bonding to Asn100 could play a prominent role in stabilizing the bound conformations of latter generation ligands, which has not been recognized previously. Overall our results suggest that molecular dynamics simulations provide important information on the dynamics of ligand-protein interactions that can be useful in guiding the design of small-molecule inhibitors of protein interfaces.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18780145     DOI: 10.1007/s10822-008-9237-0

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  31 in total

1.  Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies.

Authors:  A M Petros; D G Nettesheim; Y Wang; E T Olejniczak; R P Meadows; J Mack; K Swift; E D Matayoshi; H Zhang; C B Thompson; S W Fesik
Journal:  Protein Sci       Date:  2000-12       Impact factor: 6.725

Review 2.  Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Authors:  Michelle R Arkin; James A Wells
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

Review 3.  Strategies for targeting protein-protein interactions with synthetic agents.

Authors:  Hang Yin; Andrew D Hamilton
Journal:  Angew Chem Int Ed Engl       Date:  2005-07-04       Impact factor: 15.336

4.  Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.

Authors:  Michael D Wendt; Wang Shen; Aaron Kunzer; William J McClellan; Milan Bruncko; Thorsten K Oost; Hong Ding; Mary K Joseph; Haichao Zhang; Paul M Nimmer; Shi-Chung Ng; Alexander R Shoemaker; Andrew M Petros; Anatol Oleksijew; Kennan Marsh; Joy Bauch; Tilman Oltersdorf; Barbara A Belli; Darlene Martineau; Stephen W Fesik; Saul H Rosenberg; Steven W Elmore
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

5.  Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.

Authors:  Milan Bruncko; Thorsten K Oost; Barbara A Belli; Hong Ding; Mary K Joseph; Aaron Kunzer; Darlene Martineau; William J McClellan; Michael Mitten; Shi-Chung Ng; Paul M Nimmer; Tilman Oltersdorf; Cheol-Min Park; Andrew M Petros; Alexander R Shoemaker; Xiaohong Song; Xilu Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg; Steven W Elmore
Journal:  J Med Chem       Date:  2007-01-26       Impact factor: 7.446

6.  Modeling backbone flexibility to achieve sequence diversity: the design of novel alpha-helical ligands for Bcl-xL.

Authors:  Xiaoran Fu; James R Apgar; Amy E Keating
Journal:  J Mol Biol       Date:  2007-05-05       Impact factor: 5.469

7.  Canonical dynamics: Equilibrium phase-space distributions.

Authors: 
Journal:  Phys Rev A Gen Phys       Date:  1985-03

8.  Design, synthesis, and computational studies of inhibitors of Bcl-XL.

Authors:  Cheol-Min Park; Tetsuro Oie; Andrew M Petros; Haichao Zhang; Paul M Nimmer; Rodger F Henry; Steven W Elmore
Journal:  J Am Chem Soc       Date:  2006-12-20       Impact factor: 15.419

9.  Molecular dynamics study of peptide segments of the BH3 domain of the proapoptotic proteins Bak, Bax, Bid and Hrk bound to the Bcl-xL and Bcl-2 proteins.

Authors:  Marta Pinto; Juan J Perez; Jaime Rubio-Martinez
Journal:  J Comput Aided Mol Des       Date:  2004-01       Impact factor: 3.686

Review 10.  The role of the Bcl-2 protein family in cancer.

Authors:  Leigh Coultas; Andreas Strasser
Journal:  Semin Cancer Biol       Date:  2003-04       Impact factor: 15.707

View more
  4 in total

1.  Understanding the stereospecific interactions of 3-deoxyphosphatidylinositol derivatives with the PTEN phosphatase domain.

Authors:  Qin Wang; Yang Wei; Madhusoodanan Mottamal; Mary F Roberts; Goran Krilov
Journal:  J Mol Graph Model       Date:  2010-05-20       Impact factor: 2.518

2.  Atomic analysis of protein-protein interfaces with known inhibitors: the 2P2I database.

Authors:  Raphaël Bourgeas; Marie-Jeanne Basse; Xavier Morelli; Philippe Roche
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

3.  BcL-xL conformational changes upon fragment binding revealed by NMR.

Authors:  Clémentine Aguirre; Tim Ten Brink; Olivier Walker; Florence Guillière; Dany Davesne; Isabelle Krimm
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

4.  Crystal structure of human lysosomal acid lipase and its implications in cholesteryl ester storage disease.

Authors:  Francis Rajamohan; Allan R Reyes; Meihua Tu; Nicole L Nedoma; Lise R Hoth; Adam G Schwaid; Ravi G Kurumbail; Jessica Ward; Seungil Han
Journal:  J Lipid Res       Date:  2020-06-01       Impact factor: 5.922

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.